TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36816939
Drug: Long-course chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course chemoradiotherapy combined with concurrent tislelizumab (50 Gy/25 f, 2 Gy/f, 5 days/week; capecitabine 1000 mg/m2 bid, day 1-14 for three 21-day cycles; tislelizumab 200 mg, day 8 for three 21-day cycles)
Study: 36816939
Drug: Long-course chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course chemoradiotherapy combined with concurrent tislelizumab
Study: 36817467
Drug: GAD-alum administered
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum administered into lymph nodes
Study: 36817467
Drug: GAD-alum injections
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum injections
Study: 36817762
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy (OT) intervention twice a day plus standard non-pharmacological prevention measures for 5 days after surgery
Study: 36817782
Drug: Procalcitonin-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin-guided treatment (PCT)
Study: 36818595
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of mRNA vaccine
Study: 36818595
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of mRNA vaccine
Study: 36819685
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement + placebo (SU-PL)
Study: 36819685
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement + probiotics (SU-PR)
Study: 36820098
Drug: BGB-DXP593 5
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGB-DXP593 5 mg/kg
Study: 36820098
Drug: BGB-DXP593 15
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGB-DXP593 15 mg/kg
Study: 36820098
Drug: BGB-DXP593 30
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGB-DXP593 30 mg/kg
Study: 36821767
Drug: Outpatient administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outpatient administration of AUTO3
Study: 36821768
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy (2 × 10^6 cells per kg)
Study: 36821768
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy
Study: 36822031
Drug: Telephone delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone delivered problem-solving treatment
Study: 36822079
Drug: Pecan-enriched diet
Normalized name: Pecan
DrugBank: Pecan (DB10555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pecan-enriched diet (68 g of pecans/d)
Study: 36822161
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus camrelizumab therapy
Study: 36822255
Drug: Intravenous Shenfu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Shenfu injection (80mL Shenfu injection + 70mL 5% glucose injection)
Study: 36822255
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (150mL 5% glucose injection)
Study: 36822256
Drug: Adjunctive relining
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive relining stents
Study: 36822371
Drug: Vibrating capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrating capsule, once daily, 5 days a week for 8 weeks
Study: 36822371
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily, 5 days a week for 8 weeks
Study: 36822634
Drug: Ecleralimab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecleralimab (4 mg once-daily inhaled)
Study: 36822667
Drug: Durvalumab (durva)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (durva) with radiation therapy (RT) for 7 weeks followed by adjuvant durvalumab for 1 year
Study: 36822667
Drug: Durvalumab (durva)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (durva) with radiation therapy (RT) for 7 weeks
Study: 36822839
Drug: GSK3640254 (GSK'254)
Normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 (GSK'254) 200 mg once daily from Days 11 to 20 and a single dose of cocktail + GSK'254 200 mg on Day 21
Study: 36822839
Drug: GSK3640254 (GSK'254)
Normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 (GSK'254) 200 mg once daily
Study: 36823150
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day orally; neoadjuvant phase for 42 days and adjuvant phase to 12 months)
Study: 36823150
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus cisplatin (GC group; gemcitabine 1250 mg/m2, dosage not fully specified)
Study: 36823164
Drug: Home non-invasive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home non-invasive mechanical ventilation (HMV) with home oxygen therapy (HOT)
Study: 36823164
Drug: Home oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home oxygen therapy (HOT) alone
Study: 36823200
Drug: gB/MF59 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: gB/MF59 vaccine candidate
Study: 36823302
Drug: Vorasidenib 50
Normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorasidenib 50 mg once daily (q.d.)
Study: 36823302
Drug: Ivosidenib 500
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivosidenib 500 mg once daily (q.d.)
Study: 36823349
Drug: Dostarlimab 500
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks
Study: 36823559
Drug: Dialogue-based webinar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialogue-based webinar intervention facilitated by a LTCW and a medical expert, guided by an evidence-based COVID-19 vaccine decision tool.
Study: 36823559
Drug: Curated social
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curated social media web application intervention featuring interactive, dynamic content about COVID-19 and relevant vaccines.
Study: 36823559
Drug: Enhanced usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced usual practice directing participants to online public health information about COVID-19 vaccines.
Study: 36823645
Drug: Telehealth delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth delivery of treatments
Study: 36823645
Drug: Assistance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assistance with scheduling of assigned treatments
Study: 36824611
Drug: SPSPII score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPSPII score system applied before treatment
Study: 36824884
Drug: Smartphone intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smartphone intervention for medication assisted treatment
Study: 36825238
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eight blood biomarkers
Study: 36826476
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg on day 1 and day 14)
Study: 36826820
Drug: Epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (75 mg/m2) and paclitaxel (175 mg/m2) every 3 weeks for 6 cycles (EP regimen)
Study: 36826820
Drug: Epirubicin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for 4 cycles followed by paclitaxel (175 mg/m2) every 3 weeks for 4 cycles (EC-P regimen)
Study: 36826834
Drug: Intensive diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diabetes management (automated insulin delivery system)
Study: 36826995
Drug: MEDI-570 (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-570 (monoclonal antibody against ICOS) administered intravenously every 3 weeks for up to 12 cycles at doses ranging from 0.01 to 3 mg/kg.
Study: 36826996
Drug: Open-Source Automated
Normalized name: AMYLOPECTIN, UNSPECIFIED SOURCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-Source Automated Insulin Delivery AndroidAPS
Study: 36828201
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus (TAC) and mycophenolate mofetil (MMF)
Study: 36828343
Drug: Normoglycemic (glycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemic (glycemia 2.2 to 8.3 mmol/L)
Study: 36828343
Drug: Hypoglycemic (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic (at least 1 measurement <2.2 mmol/L)
Study: 36828343
Drug: Hyperglycemic (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemic (at least 1 measurement >8.3 mmol/L)
Study: 36828619
Drug: CC family
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC family history
Study: 36828643
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg at week 0, week 4, then every 8 weeks (Q8W)
Study: 36828719
Drug: Separate Administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate Administration of QIV and PCV20
Study: 36829104
Drug: Propofol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg·kg)
Study: 36829154
Drug: Iruplinalkib 180
Normalized name: Iruplinalkib
DrugBank: Iruplinalkib (DB17494)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iruplinalkib 180 mg orally once daily for a 21-day cycle with a 7-day lead-in phase at 60 mg orally once daily.
Study: 36830825
Drug: Frameless CyberKnife
Normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frameless CyberKnife SRS, doses of 70 to 105 Gy delivered in a single fraction.
Study: 36830825
Drug: Frameless CyberKnife
Normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frameless CyberKnife SRS, doses equal to or less than 85 Gy.
Study: 36830825
Drug: Frameless CyberKnife
Normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frameless CyberKnife SRS, doses of 95 and 100 Gy.
Study: 36830825
Drug: Frameless CyberKnife
Normalized name: OCTINOXATE 2.0 mL in 100 mL TOPICAL CREAM [TRACELESS SKIN RESPONSIVE TINT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frameless CyberKnife SRS, doses below 90 Gy.
Study: 36833192
Drug: CAH-X treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAH-X treatment
Study: 36834367
Drug: Epidural Steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Steroid Injection through a transforaminal approach (ESI TF)
Study: 36840749
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg QD and Sorafenib 200 mg BID (intermittent schedule)
Study: 36840749
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing schedules
Study: 36840749
Drug: EVE 10
Normalized name: Carprieve 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVE 10 mg QD and SOR 400 mg BID (intermittent schedules)
Study: 36840749
Drug: Dose reductions
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reductions
Study: 38051750
Drug: Dose-limiting toxicities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-limiting toxicities
Study: 36841318
Drug: Goreisan at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goreisan at a dose of 7.5 g daily on top of usual care
Study: 36841360
Drug: Biologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic treatment eligibility assessment
Study: 36841360
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCS) use
Study: 36841502
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (Moreau or Moscow strains)
Study: 36841502
Drug: Moreau strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moreau strain of BCG vaccine
Study: 36841540
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg intravenously every 2 weeks for up to 1 year)
Study: 36841762
Drug: Combination (exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (exercise + liraglutide)
Study: 36841790
Drug: Probiotics (Peifeikang,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Peifeikang, Live Combined Bifidobacterium, 210 mg per capsule, twice a day, four capsules each time)
Study: 36841794
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline and placebo capsules
Study: 36842439
Drug: Hyperfractionation (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionation (65 Gy in 54 fractions, given twice daily with an interfractional time interval of at least 6 h)
Study: 36842451
Drug: Sugar-sweetened beverages
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-sweetened beverages (SSBs) at high doses (≥20%E or 100 g/d)
Study: 36842451
Drug: Fruits at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruits at lower doses (≤10%E or 50 g/d)
Study: 36842849
Drug: relmacabtagene autoleucel
Normalized name: relmacabtagene autoleucel
DrugBank: Relmacabtagene autoleucel (DB18979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: relmacabtagene autoleucel (relma-cel) infusion after lymphodepletion chemotherapy
Study: 36842886
Drug: AKS-452 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKS-452 (90 µg single dose)
Study: 36842886
Drug: AKS-452 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKS-452 (two 45 µg doses 28 days apart)
Study: 36842964
Drug: High-dose tandospirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tandospirone (60 mg/d)
Study: 36842964
Drug: Low-dose tandospirone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tandospirone (30 mg/d)
Study: 36843239
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy for 3 months
Study: 36845050
Drug: Oral ketone
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketone ester (395 mg/kg)
Study: 36845633
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (maximal safe resection and postoperative chemoradiotherapy with 60 Gy/30 fr and concurrent/adjuvant temozolomide)
Study: 36845705
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks) and escalating doses of IL-2 (6,000 or 60,000 or 600,000 IU/kg IV bolus every 8 hours up to 14 doses per cycle)
Study: 36845705
Drug: High-dose IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IL-2 therapy in combination with pembrolizumab
Study: 36847333
Drug: Daily blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily blueberry consumption for 12 weeks
Study: 36847952
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist (GLP-1RA)
Study: 36848061
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT), Mindfulness-based stress reduction (MBSR), Behavior therapy (BT)
Study: 36848113
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone (INC group) - 1 application per nostril, once per day for 12 weeks
Study: 36848113
Drug: 3-mL sodium
Normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mL sodium chloride (NaCl), 0.9%, solution in a nasal nebulizer once a day for 12 weeks (control group)
Study: 36848311
Drug: Corticosteroids (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (administered to 18 patients, 19% of TMP-SMZ group)
Study: 36848311
Drug: TMP-SMZ treatment
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMZ treatment
Study: 36848639
Drug: Pegcetacoplan 1080
Normalized name: pegcetacoplan 1080 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegcetacoplan 1080 mg subcutaneously twice weekly for 26 weeks
Study: 36848897
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation along with oral rehydration solution (ORS)
Study: 38685922
Drug: Intensive non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive non-surgical treatment
Study: 36849161
Drug: Micro-particle curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-particle curcumin (90 mg/day)
Study: 36849205
Drug: Adjunctive triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive triamcinolone acetonide (TA)
Study: 36849212
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion (16 pmol/kg/min)
Study: 36849212
Drug: Semaglutide injections
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide injections (0.5 mg once-weekly)
Study: 36849212
Drug: Continuous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous placebo (subcutaneous)
Study: 36849797
Drug: onabotulinumtoxinA (onabotA)
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: onabotulinumtoxinA (onabotA) injections
Study: 36849838
Drug: Inactivated COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated COVID-19 vaccine (two-dose vaccination)
Study: 36849838
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (two-dose vaccination)
Study: 36849955
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug control (either Chidamide or Cladribine)
Study: 36849969
Drug: Masitinib 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib 4.5 mg/kg/day
Study: 36849969
Drug: Masitinib 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib 6.0 mg/kg/day (titrated)
Study: 36849990
Drug: Real bihemispheric
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real bihemispheric tDCS (20 min, 2 mA, during task practice twice daily for 20 sessions in two weeks)
Study: 36851177
Drug: WIV04 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WIV04 vaccine (5μg of inactivated SARS-CoV-2 virion adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension)
Study: 36851177
Drug: HB02 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB02 vaccine (4μg of inactivated SARS-CoV-2 virion adsorbed into aluminum hydroxide in a 0.5 mL aqueous suspension)
Study: 36851196
Drug: CV0501 mRNA-based
Normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV0501 mRNA-based Omicron COVID-19 vaccination (specific dosage and duration not mentioned)
Study: 36851196
Drug: Bivalent vaccine
Normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent vaccine formulations (specific dosage and duration not mentioned)
Study: 36851204
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg + 5 µg vaccine formulation
Study: 36851204
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg + 20 µg vaccine formulation
Study: 36851662
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 vaccine with previous infection
Study: 36852100
Drug: Guided relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided relaxation intervention group (video sessions ranging from 2 to 20 min each viewed daily over 5 weeks)
Study: 36852107
Drug: Sofosbuvir plus
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir plus velpatasvir (SOF/VEL) 400/100 mg once daily for 8 weeks
Study: 36852705
Drug: Linerixibat 40
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linerixibat 40 mg BID
Study: 36852998
Drug: COVID-HIGIV 100
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-HIGIV 100 mg/kg
Study: 36852998
Drug: COVID-HIGIV 200
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-HIGIV 200 mg/kg
Study: 36852998
Drug: COVID-HIGIV 400
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-HIGIV 400 mg/kg
Study: 36853611
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug approach with standard of care (static cold storage)
Study: 36853611
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug approach
Study: 36853612
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (1.5 g), thiamine hydrochloride (100 mg), and hydrocortisone sodium succinate (50 mg) every 6 hours for 96 hours
Study: 36853612
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C, thiamine, and hydrocortisone